Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD study of ANX005 in Guillain-Barré syndrome
2025-522664-32-00Phase 3Authorised
- Sponsor
- Annexon Biosciences
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of tanruprubart in Guillain-Barré syndrome (GBS), sponsored by Annexon Biosciences. Primary endpoint: Noncompartmental pharmacokinetic parameters of ANX005 in serum through Week 2. Planned start Dec 2025; status: authorised.
02
Drugs
tanruprubart
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on 2025-522664-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522664-32-00.